Vera Salus Ricerca Srl (VSR), in collaboration with the Departments of Drug & Health Sciences and Biomedical & Biotechnological Sciences of Catania University, just published a new study in the Journal of Medicinal Chemistry detailing the antimetastatic activity of novel multiligand drugs with simultaneous regulation of sigma-receptor and epigenetic pathways. The paper is entitled Haloperidol Metabolite II Valproate Ester ( S)-(-)-MRJF22: Preliminary Studies as a Potential Multifunctional Agent Against Uveal Melanoma and identify a promising drug-candidate for the treatment of Uveal Melanoma, an aggressive cancer of the eye with high metastasis and mortality rates.

Haloperidol Metabolite II Valproate Ester (S)-(−)-MRJF22: Preliminary Studies as a Potential Multifunctional Agent Against Uveal Melanoma